Current Report Filing (8-k)
October 16 2017 - 5:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
October 10, 2017
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
0-35737
(Commission
File Number)
|
94-3306718
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 1.01.
|
Entry into Material Definitive Agreement.
|
On October 10,
2017, Northwest Biotherapeutics, Inc. (the “Company”) entered into an agreement to lease to Commodities Centre, a
commodity storage and distribution firm domiciled in the U.K., an existing approximately 275,000 square foot warehouse
building on the Company’s property in Sawston, U.K. The term of the lease will be five years,
with the potential for the tenant to discontinue at three years and five months. The
tenant will undertake at least £850,000 (approximately $1,126,000) of repairs and improvements to the building in
return for five and a half months of free rent (which began upon execution of the lease and ends on March 24, 2018). Thereafter, the
tenant will pay rent at an annualized rate of £757,896 (approximately $1,004,057) for the first year, and thereafter
rent at an annualized rate of £1,092,143 (approximately $1,446,865) for each year or partial year for the rest of the
lease term, plus VAT. The tenant will also pay a proportional share of the common costs and the insurance costs for the
overall site. The tenant will pay for its own utilities and other costs for use of the warehouse.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
Date: October 16, 2017
|
By:
/s/ Les Goldman
|
|
Name: Les Goldman
Title: Senior Vice President
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024